Denosumab Administration After Spinal Cord Injury
Status unconfirmed · Phase 4 · Has a placebo group
Conditions studied: Osteoporosis, Spinal Cord Injury
In brief
Sublesional bone loss after acute spinal cord injury (SCI) is sudden, progressive, and dramatic. After depletion of bone mass and the loss of architectural integrity, it may be difficult, if even possible, to restore skeletal mass and strength. Denosumab is a relative new, highly potent anti-resorptive agent that has proven efficacy in postmenopausal osteoporosis to improve bone mass and in solid tumor patients to prevent a skeletal-related event to a greater extent than that with bisphosphonate administration. In persons with complete motor lesions, bisphosphonates have not been effective at reducing bone loss at the knee, the site of greatest relevance because of its increased risk of fracture. Anti-RANKL therapy appears to be more potent than bisphosphonates in animal models of bone loss due to immobilization, suggesting that treatment with denosumab may prove to be an efficacious therapy for persons with acute SCI to preserve bone mass and strength.
Key facts
- Study ID
- NCT01983475
- Run by
- James J. Peters Veterans Affairs Medical Center
- People needed
- 24
- Starts
- 2015-01-01
- Expected to finish
- 2020-05-01
- Last updated by the study team
- 2019-03-08
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Complete motor SCI [American Spinal Injury Association Impairment Scale (AIS) grade A and B];
- Duration of injury <12 weeks; and
- Males between the ages of 18 and 65 years old and females between the ages of 18 and 50 years old.
You may not qualify if…
- Extensive life-threatening injuries in addition to SCI;
- Acute fracture or extensive bone trauma;
- History of prior bone disease (Paget's hyperparathyroidism, osteoporosis, etc.)
- Post menopausal women;
- Men with known hypogonadism prior to SCI;
- Anabolic or Steroid hormonal therapy; within the past year and longer than six months;
- Hyperthyroidism;
- Cushing's disease or syndrome;
- Severe underlying chronic disease;
- Heterotopic ossification of the knee region (HO limited to the hip region only will not exclude subject participation);
- History of chronic alcohol abuse;
- Diagnosis of Hypocalcemia;
- Pregnancy;
- Existing dental condition/dental infection
- Any patient taking a bisphosphonate for heterotopic ossification (HO);
- Current diagnosis of cancer or history of cancer; and
- Any patient receiving moderate or high dose corticosteroids (>40 mg/d prednisone or an equivalent dose of other corticosteroid) for longer than one week, not including drug administered in an attempt to preserve neurological function at the time of acute SCI.
Where it is running
- Kessler Institute for Rehabilitation — West Orange, New Jersey, United States (enrolling)
- James J. Peters VA Medical Center — The Bronx, New York, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.